Eysuvis was trialed against placebo so no data vs. Lotemax and Lotemax wasn't trialed for DED flares. The SE profile is benign...AEs (2.9% vs 1.5% placebo) and IOP elevation (0/449) similar to placebo.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.